Literature DB >> 16709693

Hospital volume of throughput and periprocedural and medium-term adverse events after percutaneous coronary intervention: retrospective cohort study of all 17,417 procedures undertaken in Scotland, 1997-2003.

K R Burton1, R Slack, K G Oldroyd, A C H Pell, A D Flapan, I R Starkey, H Eteiba, K P Jennings, R J Northcote, W Stewart Hillis, J P Pell.   

Abstract

OBJECTIVE: To determine whether percutaneous coronary intervention (PCI) hospital volume of throughput is associated with periprocedural and medium-term events, and whether any associations are independent of differences in case mix.
DESIGN: Retrospective cohort study of all PCIs undertaken in Scottish National Health Service hospitals over a six-year period.
METHODS: All PCIs in Scotland during 1997-2003 were examined. Linkage to administrative databases identified events over two years' follow up. The risk of events by hospital volume at 30 days and two years was compared by using logistic regression and Cox proportional hazards models.
RESULTS: Of the 17,417 PCIs, 4900 (28%) were in low-volume hospitals and 3242 (19%) in high-volume hospitals. After adjustment for case mix, there were no significant differences in risk of death or myocardial infarction. Patients treated in high-volume hospitals were less likely to require emergency surgery (adjusted odds ratio 0.18, 95% confidence interval (CI) 0.07 to 0.54, p = 0.002). Over two years, patients in high-volume hospitals were less likely to undergo surgery (adjusted hazard ratio 0.52, 95% CI 0.35 to 0.75, p = 0.001), but this was offset by an increased likelihood of further PCI. There was no net difference in coronary revascularisation or in overall events.
CONCLUSION: Death and myocardial infarction were infrequent complications of PCI and did not differ significantly by volume. Emergency surgery was less common in high-volume hospitals. Over two years, patients treated in high-volume centres were as likely to undergo some form of revascularisation but less likely to undergo surgery.

Entities:  

Mesh:

Year:  2006        PMID: 16709693      PMCID: PMC1861259          DOI: 10.1136/hrt.2005.086736

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  17 in total

1.  Effects of hospital volume on long-term outcomes after percutaneous transluminal coronary angioplasty after acute myocardial infarction.

Authors:  Michel Doucet; Mark Eisenberg; Lawrence Joseph; Louise Pilote
Journal:  Am Heart J       Date:  2002-07       Impact factor: 4.749

2.  In-hospital outcomes after percutaneous coronary intervention in Canada: 1992/93 to 2000/01.

Authors:  Shelina M Jamal; Fiona M Shrive; William A Ghali; Merrill L Knudtson; Mark J Eisenberg
Journal:  Can J Cardiol       Date:  2003-06       Impact factor: 5.223

3.  Learning and the evolution of medical technologies: the diffusion of coronary angioplasty.

Authors:  Vivian Ho
Journal:  J Health Econ       Date:  2002-09       Impact factor: 3.883

4.  Certificate of need, volume, and percutaneous transluminal coronary angioplasty outcomes.

Authors:  Vivian Ho
Journal:  Am Heart J       Date:  2004-03       Impact factor: 4.749

5.  Percutaneous coronary intervention: recommendations for good practice and training.

Authors:  K D Dawkins; T Gershlick; M de Belder; A Chauhan; G Venn; P Schofield; D Smith; J Watkins; H H Gray
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

6.  Coronary revascularisation: why do rates vary geographically in the UK?

Authors:  N Black; S Langham; M Petticrew
Journal:  J Epidemiol Community Health       Date:  1995-08       Impact factor: 3.710

7.  Relation between operator and hospital volume and outcomes following percutaneous coronary interventions in the era of the coronary stent.

Authors:  P D McGrath; D E Wennberg; J D Dickens; A E Siewers; F L Lucas; D J Malenka; M A Kellett; T J Ryan
Journal:  JAMA       Date:  2000-12-27       Impact factor: 56.272

8.  The current cost of angina pectoris to the National Health Service in the UK.

Authors:  S Stewart; N F Murphy; N Murphy; A Walker; A McGuire; J J V McMurray
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

9.  Hospital percutaneous coronary intervention volume and patient mortality, 1998 to 2000: does the evidence support current procedure volume minimums?

Authors:  Andrew J Epstein; Saif S Rathore; Kevin G M Volpp; Harlan M Krumholz
Journal:  J Am Coll Cardiol       Date:  2004-05-19       Impact factor: 24.094

10.  The association of hospital volumes of percutaneous transluminal coronary angioplasty with adverse outcomes, length of stay, and charges in California.

Authors:  K A Phillips; H S Luft; J L Ritchie
Journal:  Med Care       Date:  1995-05       Impact factor: 2.983

View more
  5 in total

Review 1.  [Acute myocardial infarction: acute coronary intervention at any hospital versus acute coronary intervention at specialized centers only].

Authors:  Ralf Zahn; Uwe Zeymer
Journal:  Herz       Date:  2009-05       Impact factor: 1.443

Review 2.  Percutaneous Coronary Intervention: Relationship Between Procedural Volume and Outcomes.

Authors:  Apurva O Badheka; Sidakpal S Panaich; Shilpkumar Arora; Nilay Patel; Nileshkumar J Patel; Chirag Savani; Abhishek Deshmukh; Mauricio G Cohen
Journal:  Curr Cardiol Rep       Date:  2016-04       Impact factor: 2.931

3.  Distinct features of recombinant rat vanilloid receptor-1 expressed in various expression systems.

Authors:  J Lázár; T Szabó; L Kovács; P M Blumberg; T Bíró
Journal:  Cell Mol Life Sci       Date:  2003-10       Impact factor: 9.261

4.  The incidence and cost of cardiac surgery adverse events in Australian (Victorian) hospitals 2003-2004.

Authors:  Jonathon Pouya Ehsani; Stephen J Duckett; Terri Jackson
Journal:  Eur J Health Econ       Date:  2007-03-09

Review 5.  A Systematic Review and Meta-Analysis of the Relationship Between Hospital Volume and the Outcomes of Percutaneous Coronary Intervention.

Authors:  Xiaojun Lin; Hongbing Tao; Miao Cai; Aihua Liao; Zhaohui Cheng; Haifeng Lin
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.